Prucalopride for the treatment of chronic constipation in women

TA211 Constipation (women) - prucalopride: review decision - January 2014 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 126 KB)

TA211 Constipation (women) - prucalopride: review proposal - November 2013 information

Appendix A: provisional matrix of stakeholders (PDF 103 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 449 KB)

Constipation (women) - prucalopride: press release  information

2010/179 NICE recommends prucalopride for chronic constipation in women (PDF 82 KB)

Constipation (women) - prucalopride: Equality Impact Assessment form (PDF 75 KB)

Constipation (women) - prucalopride: final appraisal determination information

Constipation (women) - prucalopride: final appraisal determination (PDF 249 KB)

Constipation (women) - prucalopride: response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 367 KB)

Constipation (women) - prucalopride: consultee and commentator comments on the ACD

Constipation (women) - prucalopride: manufacturer

Constipation (women) - prucalopride: Movetis comments (PDF 25 KB)

Constipation (women) - prucalopride: Movetis letter (PDF 43 KB)

Constipation (women) - prucalopride: British Society of Gastroenterology and Royal College of Physicians (joint submission) (PDF 39 KB)

Constipation (women) - prucalopride: commentators

Constipation (women) - prucalopride: Norgine Pharmaceuticals Ltd comments on cost-effectiveness assessment (PDF 252 KB)

Constipation (women) - prucalopride: Norgine Pharmaceuticals Ltd comments on clinical assessment (PDF 85 KB)

Constipation (women) - prucalopride: West Midlands Health Technology Assessment Collaboration comments (PDF 135 KB)

Constipation (women) - prucalopride: comments on the ACD received from the public through the NICE website

Constipation (women) - prucalopride: web comments (PDF 291 KB)

Constipation (women) - prucalopride: public comments 1 (PDF 307 KB)

Constipation (women) - prucalopride: public comments 2 (PDF 7.3 KB)

Constipation (women) - prucalopride: press release on the draft guidance consultation information

2010/105 Chronic constipation in women (PDF 50 KB)

Constipation (women) - prucalopride: appraisal consultation

Constipation (women) - prucalopride: appraisal consultation document information

Constipation (women) - prucalopride: appraisal consultation: evaluation report

Constipation (women) - prucalopride: pre-meeting briefing (PDF 221 KB)

Constipation (women) - prucalopride: evidence review group report (PDF 657 KB)

Constipation (women) - prucalopride: manufacturer response to the evidence review group report

Constipation (women) - prucalopride: Movetis letter to accompany response to ERG report (PDF 81 KB)

Constipation (women) - prucalopride: Movetis critique of ERG report (PDF 174 KB)

Constipation (women) - prucalopride: non-manufacturer submissions

Constipation (women) - prucalopride: PromoCon statement (PDF 36 KB)

Constipation (women) - prucalopride: British Society of Gastroenterology statement (PDF 45 KB)

Constipation (women) - prucalopride: NHS Greenwich (PDF 31 KB)

Constipation (women) - prucalopride: Movetis (PDF 5.44 MB)

Constipation (women) - prucalopride: NICE clarification letter (PDF 66 KB)

Constipation (women) - prucalopride: Movetis response to NICE clarification letter (PDF 458 KB)

Constipation (women) - prucalopride: expert statements

Constipation (women) - prucalopride: Whorwell (PDF 34 KB)

Constipation (women) - prucalopride: Emmanuel (PDF 13 KB)

Constipation (women) - prucalopride: Rogers (PDF 11 KB)

Constipation (women) - prucalopride: Amin (PDF 14 KB)

Constipation (women) - prucalopride: final scope (PDF 37 KB)

Constipation (women) - prucalopride: response to consultees and commentators on the draft scope (PDF 59 KB)

Constipation (women) - prucalopride: response to consultees and commentators on the provisional matrix (PDF 23 KB)